Martos, TamaraSaint-Gerons Trecu, MartaMasfarré, LauraCastro-Henriques, MariaMartínez-García, MariaServitja Tormo, SoniaAlbanell Mestres, Joan2025-03-282025-03-282024Martos T, Saint-Gerons M, Masfarre L, Castro-Henriques M, Martinez-Garcia M, Servitja S, et al. Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports. Front Oncol. 2024 Dec 19;14:1430341. DOI: 10.3389/fonc.2024.14303412234-943Xhttp://hdl.handle.net/10230/70036The most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 inhibitor (abemaciclib, ribociclib, or palbociclib) combined with endocrine therapy. Despite CDK4/6 inhibitors being part of routine care in the last few years, new adverse events continue to be reported. Here, we report two cases of palinopsia, a rare neurological visual disturbance that refers to the persistence or recurrence of a visual image after the removal of visual stimuli in patients treated with ribociclib and letrozole. Neuro-ophthalmological assessments and brain MRIs did not find any organic cause. However, palinopsia was related in a time- and dose-dependent manner to the intake of ribociclib. Following a one-level dose reduction of ribociclib, palinopsia was mild and well tolerated. Both patients continued the treatment with ribociclib, with one of them for almost 2 years. Based on the identification of two cases in our hospital in a short period of time, it is tempting to suggest that ribociclib-related palinopsias may not be uncommon. We propose that physicians should be aware of this ribociclib-associated adverse event. Patients presenting this symptom should undergo a routine workup (neuro-ophthalmological assessment and brain MRI) and, if negative, be reassured of its relation with ribociclib as well as the safety of continuing on this drug.application/pdfeng© 2024 Martos, Saint-Gerons, Masfarre, Castro-Henriques, Martinez-Garcia, Servitja and Albanell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.info:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fonc.2024.1430341Adverse eventsBreast cancerOphthalmologic toxicityPalinopsiasRibociclibinfo:eu-repo/semantics/openAccess